Table 2 Endpoints by allocated treatment for the 176 children with data for six months after trial entry
Artemether-lumefantrine (n = 87) | Artemisinin-naphthoquine (n = 89) | P -value | |
|---|---|---|---|
Primary outcome | |||
Clinical malaria within six months following initial treatment | 20/87 (23) | 10/89 (11.2) | 0.046 |
Median time to first malarial illness (days) | 64 [50–146] | 116 [77–130] | 0.20 |
Secondary outcome | |||
Incidence of non-malarial illnesses within six months | 21/87 (24.1) | 16/89 (18.0) | 0.36 |
Median time to first non-malarial illness (days) | 123 [80–149] | 107 [92–166] | 0.77 |